Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease

BACKGROUND: Inflammatory bowel disease (IBD) is often managed with anti‐tumour necrosis factor‐α therapy (anti‐TNFα), but treatment efficacy is compromised by high annual rates of loss of response (13%‐21% per patient‐year). AIMS: To assess whether the incidence of loss of response decreases with lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultheiss, Johannes P. D., Mahmoud, Remi, Louwers, Jonas M., van der Kaaij, Michiel T., van Hellemondt, Boris P., van Boeckel, Petra G., Mahmmod, Nofel, Jharap, Bindia, Fidder, Herma H., Oldenburg, Bas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Duration of Response to Anti‐tnf Agents in IBD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292495/
https://www.ncbi.nlm.nih.gov/pubmed/34559428
http://dx.doi.org/10.1111/apt.16605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292495/
https://www.ncbi.nlm.nih.gov/pubmed/34559428
http://dx.doi.org/10.1111/apt.16605

Ejemplares similares